166 related articles for article (PubMed ID: 38517376)
21. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
22. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Yang Y; Xiao W; Liu R; Gao L; Chen J; Kan H
J Immunol Res; 2022; 2022():4983532. PubMed ID: 36405011
[TBL] [Abstract][Full Text] [Related]
23. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
24. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
25. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
26. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
27. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
29. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
31. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
32. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
33. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
Wang Y; Wan X; Du S
Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
[TBL] [Abstract][Full Text] [Related]
34. Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma.
Xiong C; Pan G; Wang H; Meng G; Yan L; Li R; Yan Y; Yang Y; Zhang X; Yang C; Dong Z; Li T
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16869-16884. PubMed ID: 37736789
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
36. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L
Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
38. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
[TBL] [Abstract][Full Text] [Related]
39. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]